Sterling Capital Management’s Bright Minds Biosciences DRUG Stock Holding History
Bought
Maintained
Sold
Other funds holding DRUG
Sterling Capital Management's DRUG Position: Q3 2026 in Review
Sterling Capital Management increased its Bright Minds Biosciences (DRUG) stake by 835% in Q3 2026, buying an estimated $15.3K and bringing the position to 243 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2431.
Sterling Capital Management first reported a position in DRUG in Q2 2025 and has held it in 6 quarters since. 110 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.
- Sterling Capital Management held 243 shares of Bright Minds Biosciences worth $12.1K as of Q3 2026.
- Sterling Capital Management bought 217 Bright Minds Biosciences shares in Q3 2026, an estimated $15.3K.
- Bright Minds Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2431 holding.
- Sterling Capital Management first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 6 quarters since.
- 110 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.